IDEXX Laboratories, Inc. (IDXX) VP Sells $666,807.51 in Stock

Share on StockTwits

IDEXX Laboratories, Inc. (NASDAQ:IDXX) VP Jacqueline Studer sold 3,313 shares of the company’s stock in a transaction that occurred on Tuesday, November 6th. The shares were sold at an average price of $201.27, for a total transaction of $666,807.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jacqueline Studer also recently made the following trade(s):

  • On Tuesday, August 21st, Jacqueline Studer sold 11,619 shares of IDEXX Laboratories stock. The shares were sold at an average price of $244.03, for a total transaction of $2,835,384.57.

Shares of NASDAQ:IDXX traded up $7.52 during mid-day trading on Wednesday, hitting $209.79. The stock had a trading volume of 550,300 shares, compared to its average volume of 505,226. The company has a market cap of $17.74 billion, a PE ratio of 63.96, a price-to-earnings-growth ratio of 1.87 and a beta of 0.82. IDEXX Laboratories, Inc. has a 12-month low of $146.09 and a 12-month high of $256.22.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, November 1st. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. IDEXX Laboratories had a net margin of 15.19% and a negative return on equity of 994.76%. The business had revenue of $545.00 million during the quarter, compared to the consensus estimate of $545.66 million. During the same quarter in the prior year, the firm earned $0.76 EPS. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 4.19 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Candriam Luxembourg S.C.A. lifted its position in IDEXX Laboratories by 5.1% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 5,924 shares of the company’s stock worth $1,479,000 after buying an additional 289 shares in the last quarter. AGF Investments Inc. lifted its position in IDEXX Laboratories by 1.8% in the 3rd quarter. AGF Investments Inc. now owns 357,585 shares of the company’s stock worth $89,275,000 after buying an additional 6,487 shares in the last quarter. JPMorgan Chase & Co. lifted its position in IDEXX Laboratories by 12.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 379,302 shares of the company’s stock worth $94,697,000 after buying an additional 41,716 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in IDEXX Laboratories by 2.3% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 269,085 shares of the company’s stock worth $67,180,000 after buying an additional 5,988 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in IDEXX Laboratories by 82.9% in the 3rd quarter. SG Americas Securities LLC now owns 38,694 shares of the company’s stock worth $9,660,000 after buying an additional 17,538 shares in the last quarter. Institutional investors own 91.27% of the company’s stock.

Several brokerages recently commented on IDXX. Canaccord Genuity reduced their price target on shares of IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Monday. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $274.00 price target for the company in a research report on Thursday, August 2nd. Bank of America reduced their price target on shares of IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, November 2nd. Piper Jaffray Companies upped their price target on shares of IDEXX Laboratories to $236.00 and gave the company an “overweight” rating in a research report on Wednesday, August 1st. Finally, Credit Suisse Group upped their price target on shares of IDEXX Laboratories from $255.00 to $259.00 and gave the company an “outperform” rating in a research report on Friday, August 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. IDEXX Laboratories presently has an average rating of “Buy” and a consensus target price of $252.33.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://weekherald.com/2018/11/07/idexx-laboratories-inc-idxx-vp-sells-666807-51-in-stock.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply